Cynata Therapeutics Limited
CHIA:CYP 株式レポート
Cynata Therapeutics マネジメント Cynata Therapeuticsの CEO はKilian Kellyで、 Jul2023年に任命され、 の在任期間は 1.33年です。 の年間総報酬はA$ 544.83Kで、 71.7%給与と28.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.34%を直接所有しており、その価値はA$ 145.62K 。経営陣と取締役会の平均在任期間はそれぞれ2.2年と4.4年です。
主要情報 CEO給与比率 71.7% CEO在任期間 1.3yrs CEOの所有権 0.3% 経営陣の平均在職期間 2.2yrs 取締役会の平均在任期間 4.4yrs
経営陣の近況
Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024 Sep 24
Cynata Therapeutics Limited Announces Resignation of David Atkins as Director Oct 11 Cynata Therapeutics Limited Announces Management Appointments
Cynata Therapeutics Limited, Annual General Meeting, Nov 22, 2022 Sep 27
Cynata Therapeutics Limited Appoints Janine Rolfe as Independent Non-Executive Director, Effective 1 September 2022 Aug 30
すべての更新を表示
Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024 Sep 24
New major risk - Financial position Aug 30
Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial Apr 09
Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001 Mar 06
New minor risk - Financial position Feb 24
New major risk - Share price stability Feb 13
New minor risk - Share price stability Dec 06
Cynata Therapeutics Limited Announces Resignation of David Atkins as Director Oct 11
New major risk - Financial position Aug 29 Cynata Therapeutics Limited Announces Management Appointments
New major risk - Share price stability Jun 22
Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical Trial Jan 30
Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCs Jan 09
LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation Nov 05
Cynata Therapeutics Limited Receives Notice of Allowance for Australia & Canada Cymerus Patents Oct 17
Cynata Therapeutics Limited Announces Successful Completion of Planned DSMB Review of DFU Trial Oct 12
Cynata Therapeutics Limited, Annual General Meeting, Nov 22, 2022 Sep 27
Cynata Therapeutics Limited Receives Grant Award to Fund Study of Cynata Mscs in Heart Disease from Australian Government National Health and Medical Research Council Sep 26
Cynata Therapeutics Limited Appoints Janine Rolfe as Independent Non-Executive Director, Effective 1 September 2022 Aug 30
Cynata Therapeutics Limited Announces Preclinical Study Showing Optimisation of CymerusTM MSCs for Coronary Artery Disease Published in Leading Peer-Reviewed Journal Aug 29
Cynata Therapeutics Limited Receives Notice of Allowance from US Patent Office for Use of the Cymerus MSCs in Asthma Jul 14
Cynata Therapeutics Limited Announces the Completion of A Pre-Clinical Study That Has Provided Further Evidence in Support of the Highly Potent Anti-Inflammatory Effects of Cynata's Proprietary Cymerus MSCs Jun 14
Cynata Therapeutics Limited Adds New Site for MEMD Clinical Trial May 30
United States Food and Drug Administration Clears IND for Cynata Therapeutics Limited's Phase 2 Clinical Trial of CYP-001 in GvHD May 27
Cynata Therapeutics Limited Advances Clinical Trial in Diabetic Foot Ulcers Apr 21
Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan Jan 28
Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan Jan 27
Cynata Therapeutics Limited Commences DFU Clinical Trial Dec 23
Cynata Therapeutics Limited Receives Approval by the Central Adelaide Local Health Network Human Research Ethics Committee to Commence A Clinical Trial Jul 01
Cynata Therapeutics Limited Progresses Toward Clinical Trial in Diabetic Foot Ulcers Jun 30
Cynata Therapeutics Limited Announces First Patient Enrolled in Cynata Mend Clinical Trial May 24
Cynata Therapeutics Limited to Investigate New Study of the High Potency of Cymerus MSCs Mar 03
New 90-day low: AU$0.65 Feb 25
New 90-day low: AU$0.74 Dec 11
Cynata Therapeutics Limited Announces Phase 3 Osteoarthritis Clinical Trial Commences Nov 11
Cynata Therapeutics Limited Announces Positive Efficacy Data from A Study of Cymerustm Mesenchymal Stem Cells Sep 24
New 90-day high: AU$1.02 Sep 16
New 90-day high - AU$0.80 Aug 18
CEO報酬分析 Cynata Therapeutics の収益と比較して、Kilian Kelly の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Jun 30 2024 AU$545k AU$391k -AU$10m
Mar 31 2024 n/a n/a -AU$12m
Dec 31 2023 n/a n/a -AU$14m
Sep 30 2023 n/a n/a -AU$14m
Jun 30 2023 AU$413k AU$334k -AU$14m
Mar 31 2023 n/a n/a -AU$12m
Dec 31 2022 n/a n/a -AU$9m
Sep 30 2022 n/a n/a -AU$7m
Jun 30 2022 AU$499k AU$313k -AU$5m
Mar 31 2022 n/a n/a -AU$5m
Dec 31 2021 n/a n/a -AU$4m
Sep 30 2021 n/a n/a -AU$6m
Jun 30 2021 AU$737k AU$300k -AU$8m
Mar 31 2021 n/a n/a -AU$7m
Dec 31 2020 n/a n/a -AU$6m
Sep 30 2020 n/a n/a -AU$5m
Jun 30 2020 AU$472k AU$300k -AU$4m
Mar 31 2020 n/a n/a -AU$6m
Dec 31 2019 n/a n/a -AU$8m
Sep 30 2019 n/a n/a -AU$8m
Jun 30 2019 AU$449k AU$279k -AU$8m
Mar 31 2019 n/a n/a -AU$7m
Dec 31 2018 n/a n/a -AU$6m
Sep 30 2018 n/a n/a -AU$5m
Jun 30 2018 AU$357k AU$259k -AU$5m
報酬と市場: Kilianの 総報酬 ($USD 356.54K ) は、 Australian市場 ($USD 300.85K ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Kilianの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者 Dr. Kilian Kelly has been Chief Executive Officer and Managing Director at Cynata Therapeutics Limited since July 1, 2023 and has been its Director since 2023 and had been its Chief Operating Officer since ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 MD, CEO & Director 1.3yrs AU$544.83k 0.34% A$ 145.6k Chief Medical Officer 3.1yrs AU$398.72k データなし Chief Business Officer less than a year AU$379.02k データなし Company Secretary 12.6yrs AU$140.00k データなし
もっと見る
経験豊富な経営陣: CYPの経営陣は 経験豊富 であると考えられます ( 2.2年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 MD, CEO & Director 1.8yrs AU$544.83k 0.34% A$ 145.6k Independent Non-Executive Chairman 5.5yrs AU$138.77k 0.14% A$ 60.5k Independent Non-Executive Director 8.4yrs AU$68.20k 0.17% A$ 74.1k Independent Non-Executive Director 2.2yrs AU$81.69k 0.064% A$ 27.3k Independent Non-Executive Director 4.4yrs AU$68.20k 0.028% A$ 11.7k
もっと見る
経験豊富なボード: CYPの 取締役会 は 経験豊富 であると考えられます ( 4.4年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}